Skip to content

Study · Not a test of the peptide alone · 2018

2 results

A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.

Nørregaard PK, Deryabina MA, Tofteng Shelton P, Fog JU, Daugaard JR, Eriksson PO, Larsen LF, Jessen L

Diabetes, obesity & metabolism27 Jul 2017Cited by 96 (Europe PMC)

PMID28598027 (opens in a new tab)DOI10.1111/dom.13034 (opens in a new tab)PepBankPUB-28598027
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome

    In obese mice, the GIP analogue ZP4165 enhanced weight loss caused by the GLP-1 agonist liraglutide.

    In plain wordsIn obese mice, adding the GIP analogue ZP4165 to liraglutide increased weight loss.

    Peptide
    Liraglutide
    Outcome
    IncreaseBody weight loss with ZP4165 plus liraglutide
    Study

    mousen: not reported in source

    Diet-induced obese mice
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    The GIP analogue did not alter the body weight of obese mice but enhanced GLP-1-induced weight loss.
    1 context sentence
    Summary · context
    The long-term effects of ZP4165 on body weight and glycaemic control, either alone or in combination with liraglutide, were assessed in diet-induced obese mice and diabetic db/db mice.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Efficacy outcome

    In diabetic mice, 4 weeks of ZP4165 reduced glycated haemoglobin versus vehicle by an extent similar to the GLP-1 agonist liraglutide.

    In plain wordsIn diabetic mice, ZP4165 lowered glycated haemoglobin compared with vehicle by about as much as the GLP-1 agonist.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c with ZP4165 compared with the GLP-1 agonist
    Study

    mousen: not reported in source

    Diabetic db/db mice
    Comparator
    Vehicle
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    In diabetic mice, 4 weeks' dosing with ZP4165 reduced glycated haemoglobin levels vs vehicle by an extent similar to the GLP-1 agonist.
    1 context sentence
    Summary · context
    The long-term effects of ZP4165 on body weight and glycaemic control, either alone or in combination with liraglutide, were assessed in diet-induced obese mice and diabetic db/db mice.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.